Motixafortide (BKT140, BL-8040) is an orally available, highly selective inverse agonist of CXCR4 (CXC Chemokine Receptor 4). Motixafortide is a potent stem cell mobiliser and anticancer agent. BKT140 potently inhibits CXCL12 induced migration/invasion of small-cell lung cancer cells.
Orally available, highly selective inverse agonist of CXCR4
Caution
Hygroscopic
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
Leukemia, 31(11), 2336-2346 (2017)
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003
Stem Cells, 25(9), 2158-2166 (2007)
Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140
Clinical Cancer Research, 19(13), 3495-3507 (2013)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.